You are viewing an incomplete version of our website. Please click to reload the website as full version.

PARK2 antibody (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin)) (AA 288-388)

Details for Product anti-PARK2 Antibody No. ABIN393540, Supplier: Log in to see
Antigen
  • AR-JP
  • CG10523
  • Dmel\\CG10523
  • Dpark
  • dpk
  • LOC100150461
  • LPRS2
  • Park
  • PDJ
  • pdr-1
  • Prkn
  • PRKN
  • SD01679
  • si:ch211-123f21.1
  • zgc:112390
Epitope
AA 288-388
26
25
25
18
8
5
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
Reactivity
Human
203
53
42
10
6
3
3
2
2
1
1
Host
Mouse
177
22
12
Clonality (Clone)
Monoclonal ()
Conjugate
This PARK2 antibody is un-conjugated
6
6
5
5
3
3
3
3
3
3
3
3
1
1
1
Application
Immunofluorescence (IF), Western Blotting (WB)
158
72
62
36
34
28
16
15
11
2
2
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen PARK2 (AAH22014, 288 a.a. ~ 388 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 K
Clone 1H4
Isotype IgG3 kappa
Specificity PARK2 (AAH22014, 288 a.a. ~ 388 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Purification This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Alternative Name PARK2 (PARK2 Antibody Abstract)
Background Synonyms: Serine protease inhibitor J6, 47 kDa heat shock protein, Collagen-binding protein, Colligin, Serpin H1,Hsp47, Cbp1, Serpinh1
Molecular Weight 51641 DA
Gene ID 12406
Research Area Ubiquitin-related antibodies, Protein Modifications, Cell Structure
Application Notes Western blot = 1:500-1000
Comment

Background: The precise function of this gene is unknown, however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support.

Restrictions For Research Use only
Concentration 0.25mg/ml
Buffer PBS with 0.09% (w/v) sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Supplier Images
Western Blotting (WB) image for anti-PARK2 antibody (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin)) (AA 288-388) (ABIN393540) Immunofluorescence of monoclonal antibody to PARK2 on HeLa cell (antibody concentrati...
Immunohistochemistry (IHC) image for anti-PARK2 antibody (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin)) (AA 288-388) (ABIN393540) anti-Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) (AA 288-388) antibody (Image 2)
Background publications Kägi, Klein, Wood, Schneider, Pramstaller, Tadic, Quinn, van de Warrenburg, Bhatia: "Nonmotor symptoms in Parkin gene-related parkinsonism." in: Movement disorders : official journal of the Movement Disorder Society, Vol. 25, Issue 9, pp. 1279-84, 2010 (PubMed).

Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, 2010 (PubMed).

Prabhakar, Vinish, Das, Anand: "Occurrence of PARK2 mutations in a never-smoker population with Parkinson's disease in North India." in: Neuroepidemiology, Vol. 35, Issue 2, pp. 152-9, 2010 (PubMed).

Marder, Tang, Mejia-Santana, Rosado, Louis, Comella, Colcher, Siderowf, Jennings, Nance, Bressman, Scott, Tanner, Mickel, Andrews, Waters, Fahn, Ross, Cote, Frucht, Ford, Alcalay, Rezak, Novak, Friedman, Pfeiffer, Marsh, Hiner, Neils, Verbitsky, Kisselev,: "Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study." in: Archives of neurology, Vol. 67, Issue 6, pp. 731-8, 2010 (PubMed).

Suen, Narendra, Tanaka, Manfredi, Youle: "Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Issue 26, pp. 11835-40, 2010 (PubMed).